Oncology Drug Reference Sheet: Darolutamide

On August 5, 2022, the U.S. Food and Drug Administration approved darolutamide (Nubeqa^®) in combination with docetaxel in adults with metastatic hormone-sensitive prostate cancer. The approval was based on clinical trial findings demonstrating that the agent improved overall survival and significantly delayed time to pain progression compared to placebo.